Effect of topical azithromycin on corneal innate immune responses

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 5, 2011, Pages 2525-2531

  Sadrai, Zahra ^a,b   Hajrasouliha, Amir Reza ^a,b   Chauhan, Sunil ^a,b   Saban, Daniel R ^a,b   Dastjerdi, Mohammad H ^a,b   Dana, Reza ^a,b  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; MESSENGER RNA; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; CAUTERIZATION; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DRUG EFFECT; FLOW CYTOMETRY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; KERATITIS; MORPHOMETRICS; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CELL MOVEMENT; CORNEA; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE EXPRESSION; IMMUNITY, INNATE; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-1BETA; KERATITIS; LEUKOCYTES; MALE; MICE; MICE, INBRED BALB C; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79956017597     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-5658     Document Type: Article

References (35)

1. Streilein JW. Immunology and immunopathology of corneal transplantation. Chem Immunol. 1999;73:186-206.
2. Dana MR. Corneal antigen-presenting cells: diversity, plasticity, and disguise: the Cogan lecture. Invest Ophthalmol Vis Sci. 2004; 45:722-727.
3. Delves PJ, Roitt IM. The immune system: first of two parts. N Engl J Med. 2000 6;343:37-49.
4. Hamrah P, Huq SO, Liu Y, Zhang Q, Dana MR. Corneal immunity is mediated by heterogeneous population of antigen presenting cells. J Leukoc Biol. 2003;74:172-178.
5. Hamrah P, Zhang Q, Liu Y, Dana MR. Novel characterization of MHC class II-negative population of resident corneal Langerhans cell-type dendritic cells. Invest Ophthalmol Vis Sci. 2003;43:639-646.
6. Hamrah P, Zhang Q, Liu Y, Dana MR. The corneal stroma is endowed with a significant number of resident dendritic cells. Invest Ophthalmol Vis Sci. 2003;44:581-589.
7. Biswas PS, Banerjee K, Kim B, Rouse BT. Mice transgenic for IL-1 receptor antagonist protein are resistant to herpetic stromal keratitis: possible role for IL-1 in herpetic stromal keratitis pathogenesis. J Immunol. 2004;172:3736-3744.
8. Muller WA, Weigl SA, Deng XH, Phillips DM. PECAM-1 is required for transendothelial migration of leukocytes. J Exp Mecl. 1993;178: 449-460.
9. Vaporciyan AA, DeLisser HM, Yan HC, et al. Involvement of platelet-endothelial cell adhesion molecule-1 in neutrophil recruitment in vivo. Science. 1993;262:1580-1582.
10. Dana MR, Hamrah P. Corneal antigen-presenting cells: function and identity. In: Zierhut M, Stern ME, Sullivan DA, eds. Immunology of the Lacrimal Gland, Tear Film, and Ocular Surface. London: Taylor and Francis Group; 2005:141-149.
11. Baggiolini M. Chemokines in pathology and medicine. J Intern Med. 2001;250:91-104.
12. Kudoh S, Azuma A, Yamamoto M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med. 1998;157:1829-1832.
13. Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2006;174:566-570.
14. Aghai ZH, Kode A, Saslow JG, et al. Azithromycin suppresses activation of nuclear factor-kappa B and synthesis of pro-inflammatory cytokines in tracheal aspirate cells from premature infants. Pediatr Res. 2007;62:483-488.
15. Sugiyama K, Shirai R, Mukae H, et al. Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells. Clin Exp Immunol. 2007;147:540-546.
16. Dekaris I, Zhu SN, Dana MR. TNF-alpha regulates corneal Langerhans cell migration. J Immunol. 1999;162:4235-4239.
17. Hamrah P, Liu Y, Zhang Q, Dana MR. Alterations in corneal stromal dendritic cell phenotype and distribution in inflammation. Arch Ophthalmol. 2003;121:1132-1140.
18. Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, D'Amato RJ. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci. 1996;37:1625-1632.
19. Rosenbaum JT, Planck ST, Huang XN, Rich L, Ansel JC. Detection of mRNA for the cytokines, interleukin-1 alpha and interleukin-8, in corneas from patients with pseudophakic bullous keratopathy. Invest Ophthalmol Vis Sci. 1995;36:2151-2155.
20. Fukuda M, Mishima H, Otori T. Detection of interleukin-1 in the tear fluid of patients with corneal disease with or without conjunctival involvement. Jpn J Ophthalmol. 1997;41:63-66.
21. Staats HF, Lausch RN. Cytokine expression in vivo during murine herpetic stromal keratitis: effect of protective antibody therapy. J Immunol. 1993;151:277-283.
22. Biswas PS, Banerjee K, Kim B, Kinchington PR, Rouse BT. Role of inflammatory cytokine-induced cyclooxygenase 2 in the ocular immunopathologic disease herpetic stromal keratitis. J Virol. 2005; 79:10589-10600.
23. Zhu SN, Dana MR. Expression of cell adhesion molecules on limbal and neovascular endothelium in corneal inflammatory neovascularization. Invest Ophthalmol Vis Sci. 1999;40:1427-1434.
24. Culic O, Erakovic V, Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol. 2001;429:209-229.
25. Labro MT. Cellular and molecular effects of macrolides on leukocyte function, Curr Pharm. 2004;10:3067-3080.
26. Tsai WC, Standiford TJ. Immunomodulatory effects of macrolides in the lung: lessons from in-vitro and in-vivo models. Curr Pharm. 2004;10:3081-3093.
27. Dana MR, Zhu SN, Yamada J. Topical modulation of interleukin-1 activity in corneal neovascularization. Cornea. 1998;17: 403-409.
28. Connor KM, SanGiovanni JP, Lofqvist C, et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med. 2007;13:868-873.
29. Xing Z, Gauldie J, Cox G, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest. 1998;101:311-320.
30. Dana R. Comparison of topical interleukin-1 versus tumor necrosis factor-alpha blockade with corticosteroid therapy on murine corneal inflammation, neovascularization, and transplant survival (AOS thesis). Trans Am Ophthalmol Soc. 2007;105:330-343.
31. Dastjerdi MH, Saban DR, Okanobo A, et al. Effects of topical and subconjunctival bevacizumab (Avastin) in high-risk corneal transplant survival. Invest Ophthalmol Vis Sci. 2009;51:2411-2417.
32. Dastjerdi MH, Al-Arfaj KM, Nallasamy N, et al. Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol. 2009;12:381-389.
33. Liu P, Allaudeen H, Chandra R, et al. Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen. Antimicrob Agents Chemother. 2007;51:103-109.
34. Schentang JJ, Ballow CH. Tissue-directed pharmacokinetics. Am J Med. 1991;12:5-11.
35. Akpek EK, Vittitow J, Verhoeven RS, et al. Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. J Ocul Pharmacol Ther. 2009;25:433-439.